Sfoglia per AUTORE
MORO-SIBILOT D
Collezione AOU San Luigi di Orbassano

  

Items : 5

RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2024 Nov 30:S1556-0864(24)02495-X. doi: 10.1016/j.jtho.2024.11.032.
2024
AOU San Luigi di Orbassano

Nakagawa K; Garon EB; Seto T; Nishio M; Aix SP; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Nishino K; Yoh K; Shih JY; Chik JYK; Moro-Sibilot D; Puri T; Chacko Varughese S; Frimodt-Moller B; Visseren-Grul C; Reck M;

Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2022 May;167:98-106. doi: 10.1016/j.lungcan.2022.01.008. Epub 2022 Jan 22.
2022
AOU San Luigi di Orbassano

Mc Leer A; Foll M; Brevet M; Antoine M; Novello S; Mondet J; Cadranel J; Girard N; Giaj Levra M; Demontrond P; Audigier-Valette C; Letouzé E; Lantuéjoul S; Fernandez-Cuesta L; Moro-Sibilot D;

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis. in Cancer treatment and research communications / Cancer Treat Res Commun. 2021;27:100378. doi: 10.1016/j.ctarc.2021.100378. Epub 2021 Apr 19.
2021
AOU San Luigi di Orbassano

Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;

A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2019 Jan;14(1):130-134. doi: 10.1016/j.jtho.2018.08.2028. Epub 2018 Sep 11.
2019
AOU San Luigi di Orbassano

Ferrer L; Giaj Levra M; Brevet M; Antoine M; Mazieres J; Rossi G; Chiari R; Westeel V; Poudenx M; Letreut J; Gervais R; Osman G; Girard N; Toffart AC; Novello S; Moro-Sibilot D;

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.
2019
AOU San Luigi di Orbassano

Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;